日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

在 II 期 I-SPY2 临床试验中,根据临床和分子特征分析 HR+/HER2- 高危早期乳腺癌 (EBC) 患者的病理完全缓解 (pCR) 率

Huppert, L A; Wolf, D; Yau, C; Brown-Swigart, L; Hirst, G L; Isaacs, C; Pusztai, L; Pohlmann, P R; DeMichele, A; Shatsky, R; Yee, D; Thomas, A; Nanda, R; Perlmutter, J; Heditsian, D; Hylton, N; Symmans, F; Van't Veer, L J; Esserman, L; Rugo, H S

Real-time digital monitoring of continuous bladder irrigation: clinical evaluation of a sensor-based system for hematuria and catheter-associated events

实时数字监测持续膀胱冲洗:基于传感器的血尿和导尿管相关事件监测系统的临床评估

Glienke, M; Krumnau, A; Reichelt, A C; Reis, G; Steiner, C; Pohlmann, P F; Dressler, F F; Gratzke, C; Miernik, A; Schöb, D S

Mixed reality for teaching catheter placement to medical students: a randomized single-blinded, prospective trial

利用混合现实技术教授医学生导管置入术:一项随机、单盲、前瞻性试验

Schoeb, D S; Schwarz, J; Hein, S; Schlager, D; Pohlmann, P F; Frankenschmidt, A; Gratzke, C; Miernik, A

Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study

前瞻性评估HER2靶向治疗在HER2阳性乳腺癌合并心脏功能受损患者中的心脏安全性:SAFE-HEaRt研究

Lynce, F; Barac, A; Geng, X; Dang, C; Yu, A F; Smith, K L; Gallagher, C; Pohlmann, P R; Nunes, R; Herbolsheimer, P; Warren, R; Srichai, M B; Hofmeyer, M; Cunningham, A; Timothee, P; Asch, F M; Shajahan-Haq, A; Tan, M T; Isaacs, C; Swain, S M

Isolevuglandins as a gauge of lipid peroxidation in human tumors.

异戊二酸作为人类肿瘤中脂质过氧化的指标

Yan H P, Roberts L J, Davies S S, Pohlmann P, Parl F F, Estes S, Maeng J, Parker B, Mernaugh R